Alvogen
Focus: Alvogen is a publicly-traded generics and OTC manufacturer with a diversified portfolio spanning oncology, hematology, immunology, endocrinology, and cardiovascular indications. The company generates significant revenue from mature, post-LOE products with 25% concentration in exemestane.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
8-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Alvogen?
AI assessmentAlvogen is a stable but slow-growth generics player best suited for cost-conscious professionals seeking operational roles; not a destination for those pursuing innovation, career acceleration, or substantial hiring opportunities.
Why Work Here
- Established public company with cash-generating portfolio of 10 marketed generics generating $30M+ in Part D spending alone
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$8M Part DStable
Post-LOE
Anchors 25% of company revenue; aromatase inhibitor with established clinical utility but mature market.
Help build intelligence for Alvogen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.